Shopping Cart
- Remove All
Your shopping cart is currently empty
BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor that blocks the formation of Neutrophil Extracellular Traps and delays the progression of multiple myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays symptom onset and disease progression. Targeting PAD4 may be beneficial for treating multiple myeloma.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $82 | In Stock | |
| 10 mg | $145 | In Stock | |
| 25 mg | $297 | In Stock | |
| 50 mg | $533 | In Stock | |
| 100 mg | $759 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $85 | In Stock |
| Description | BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor that blocks the formation of Neutrophil Extracellular Traps and delays the progression of multiple myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays symptom onset and disease progression. Targeting PAD4 may be beneficial for treating multiple myeloma. |
| In vivo | Administration of BMS-P5 to multiple myeloma-bearing mice delays appearance of symptoms and disease progression. |
| Molecular Weight | 472.58 |
| Formula | C27H32N6O2 |
| Cas No. | 1550371-22-6 |
| Smiles | COc1cc(cc2nc(-c3cc4cccnc4n3CC3CC3)n(C)c12)C(=O)N1C[C@H](N)CC[C@@H]1C |
| Relative Density. | 1.40 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 10 mg/mL (21.16 mM), Sonication is recommended. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.